Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IPH 65

Drug Profile

IPH 65

Alternative Names: IPH-65; IPH-6501; Tetra-specific ANKET; Tetra-specific NK cell engaging antibody - Innate Pharma

Latest Information Update: 12 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innate Pharma
  • Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin-2 replacements; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma

Most Recent Events

  • 12 Jun 2024 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Late-stage disease, Second-line therapy or greater) in France (Parenteral) (NCT06088654)
  • 31 May 2024 Adverse events and pharmacodynamics data from preclinical studies in Non-Hodgkin's lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 04 Apr 2024 Innate Pharma has patent pending applications for IPH 65 in USA, the European Union, and in the multiple countries worldwide
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top